|Dr. Terence E. Winters BSc, Ph.D.||582.31k||N/A||75|
|Dr. Duane Nash M.D., J.D., M.B.A||443.37k||N/A||46|
|Mr. Robert A. Ashley M.A.||453.53k||N/A||59|
|Mr. Michael V. Swanson M.B.A||N/A||N/A||62|
|Mr. Aron P. Stern M.B.A.||N/A||N/A||63|
Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patients own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.
Vital Therapies, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.